Literature DB >> 36036360

Management of Gynecologic Cancer During COVID-19 Pandemic: South Asian Perspective.

Nilanchali Singh1,2, Neha Mishra1,3, Aarthi S Jayraj4, Prafull Ghatage2.   

Abstract

Management of gynecological cancers has suffered during the pandemic, partly due to lockdown and partly due to directing resources to manage COVID-19 patients. Modification of gynecological cancer management during this pandemic is recommended. Cervical cancer patients who present with stage IA1 disease can have a delay of up to 8 weeks for surgical treatment, considering the slow tumor growth rate. Women with stages IA2, IB1, IB2, IIA1 must undergo radical hysterectomy and lymphadenectomy within 6 to 8 weeks. In areas where surgical treatment is not available, patients should be referred for radiation therapy/areas with adequate surgical expertise. The surgical option is attractive for early cancers during the COVID era, as it involves a single visit compared to the multiple visits required for chemoradiation. The value of lymph node staging needs to be reconsidered. Neoadjuvant chemotherapy should be given preference over primary cytoreductive surgery for advanced ovarian cancers. Surgeries, which demand extended surgical time such as Hyperthermic Intraperitoneal Chemotherapy and pelvic exenterations, should be avoided during this pandemic. For patients scheduled for interval surgery after two or three neoadjuvant cycles, six cycles of chemotherapy should be considered before surgery is performed. For early-stage, low-grade endometrial cancer, consideration should be given to medical management until surgery is possible. The above recommendations have been made keeping in mind the geography, patient load, and availability of resources available to health care providers from southeast Asia. They might not be applicable globally and every practitioner should take call regarding patient's management as per availability of resources and loco-regional circumstances. The implementation of recommended international guidelines for the management of gynecologic cancers should take precedence. Each modification to the standard approach should be approved by a multidisciplinary team depending on the condition of the patients and the locoregional circumstances.

Entities:  

Keywords:  1st line treatment; adjuvant chemotherapy; burden; cancer survival; cancer, cancer therapy; chemoradiation; early diagnosis; mortality; ovarian cancer

Mesh:

Year:  2022        PMID: 36036360      PMCID: PMC9420651          DOI: 10.1177/10732748221119349

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   2.339


  41 in total

Review 1.  COVID-19 and gynecological cancer: a review of the published guidelines.

Authors:  Christina Uwins; Geetu Prakash Bhandoria; T S Shylasree; Simon Butler-Manuel; Patricia Ellis; Jayanta Chatterjee; Anil Tailor; Alexandra Stewart; Agnieszka Michael
Journal:  Int J Gynecol Cancer       Date:  2020-06-23       Impact factor: 3.437

2.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 3.  The immunobiology of cancer immunosurveillance and immunoediting.

Authors:  Gavin P Dunn; Lloyd J Old; Robert D Schreiber
Journal:  Immunity       Date:  2004-08       Impact factor: 31.745

4.  Cancer of the corpus uteri: 2021 update.

Authors:  Martin Koskas; Frédéric Amant; Mansoor Raza Mirza; Carien L Creutzberg
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

5.  COVID-19 mortality in cancer patients: a report from a tertiary cancer centre in India.

Authors:  Anurag Mehta; Smreti Vasudevan; Anuj Parkash; Anurag Sharma; Tanu Vashist; Vidya Krishna
Journal:  PeerJ       Date:  2021-01-21       Impact factor: 2.984

6.  Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans.

Authors: 
Journal:  Br J Surg       Date:  2020-06-13       Impact factor: 6.939

7.  Cancer Statistics, 2020: Report From National Cancer Registry Programme, India.

Authors:  Prashant Mathur; Krishnan Sathishkumar; Meesha Chaturvedi; Priyanka Das; Kondalli Lakshminarayana Sudarshan; Stephen Santhappan; Vinodh Nallasamy; Anish John; Sandeep Narasimhan; Francis Selvaraj Roselind
Journal:  JCO Glob Oncol       Date:  2020-07

8.  SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China.

Authors:  Jing Yu; Wen Ouyang; Melvin L K Chua; Conghua Xie
Journal:  JAMA Oncol       Date:  2020-07-01       Impact factor: 31.777

9.  A Study on Challenges to Health Care Delivery Faced by Cancer Patients in India During the COVID-19 Pandemic.

Authors:  Manasij Mitra; Maitraye Basu
Journal:  J Prim Care Community Health       Date:  2020 Jan-Dec

Review 10.  Management of cervical cancer during the corona virus disease-19 (COVID-19) era.

Authors:  Abhinav Dewan; Swarupa Mitra; Sumeet Aggarwal; Soumitra Barik; Inderjeet Kaur; Preetha Umesh; Rupali Dewan
Journal:  Br J Radiol       Date:  2020-11-20       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.